See more : Vaswani Industries Limited (VASWANI.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Grapefruit USA, Inc. (GPFT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Grapefruit USA, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Unum Group 6.250% JR NT58 (UNMA) Income Statement Analysis – Financial Results
- Korea Airport Service Co.,Ltd. (005430.KS) Income Statement Analysis – Financial Results
- Pacific Horizon Investment Trust PLC (PHI.L) Income Statement Analysis – Financial Results
- Zhuhai Port Co.,Ltd. (000507.SZ) Income Statement Analysis – Financial Results
- TLG Immobilien AG (TLG.DE) Income Statement Analysis – Financial Results
Grapefruit USA, Inc. (GPFT)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.grapefruitblvd.com
About Grapefruit USA, Inc.
Grapefruit USA, Inc. operates as a manufacturer and distributor of cannabis products in California. It primarily provides Hourglass, a time release THC+CBD-infused topical cream through online store. The company was formerly known as Grapefruit Boulevard Investments, Inc. and changed its name to Grapefruit USA, Inc. in January 2020. Grapefruit USA, Inc. was founded in 2017 and is based in Wilmington, Delaware.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 200.00 | 39.79K | 588.96K | 3.67M | 451.20K | 181.50K | 41.83K | 33.08K | 220.81K | 398.27K | 1.05M | 1.05M | 1.07M | 1.18M | 1.36M | 1.76M | 1.32M | 1.39M | 2.10M | 1.28M |
Cost of Revenue | 237.11K | 504.03K | 1.12M | 3.39M | 708.57K | 183.46K | 14.26K | 10.25K | 169.12K | 163.14K | 585.79K | 585.79K | 505.87K | 532.16K | 700.25K | 662.23K | 910.13K | 676.62K | 1.07M | 638.11K |
Gross Profit | -236.91K | -464.25K | -530.17K | 280.47K | -257.37K | -1.96K | 27.57K | 22.84K | 51.69K | 235.14K | 466.75K | 466.75K | 562.75K | 645.32K | 664.64K | 1.09M | 413.65K | 709.32K | 1.02M | 642.55K |
Gross Profit Ratio | -118,456.00% | -1,166.86% | -90.02% | 7.64% | -57.04% | -1.08% | 65.90% | 69.03% | 23.41% | 59.04% | 44.34% | 44.34% | 52.66% | 54.81% | 48.70% | 62.28% | 31.25% | 51.18% | 48.81% | 50.17% |
Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 2.40K | 108.79K | 200.69 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
General & Administrative | 0.00 | 0.00 | 1.78M | 1.32M | 1.62M | 6.32M | 1.65M | 2.70M | 1.50M | 1.36M | 1.86M | 1.86M | 0.00 | 2.47M | 2.51M | 2.28M | 2.47M | 0.00 | 0.00 | 0.00 |
Selling & Marketing | 0.00 | 0.00 | 7.66K | 169.35K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A | 688.91K | 1.73M | 1.79M | 1.49M | 1.62M | 6.32M | 1.65M | 2.70M | 1.50M | 1.36M | 1.86M | 1.86M | 2.95M | 2.47M | 2.51M | 2.28M | 2.47M | 2.75M | 1.63M | 1.92M |
Other Expenses | 0.00 | 0.00 | 371.32K | 169.35 | 0.00 | -23.33K | 87.49K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating Expenses | 688.91K | 1.73M | 1.79M | 1.49M | 1.62M | 6.32M | 1.65M | 2.70M | 1.50M | 1.36M | 1.86M | 1.86M | 2.95M | 2.47M | 2.51M | 2.28M | 2.47M | 3.01M | 2.18M | 2.66M |
Cost & Expenses | 926.02K | 2.23M | 2.91M | 4.88M | 2.33M | 6.32M | 1.67M | 2.71M | 1.67M | 1.52M | 2.45M | 2.45M | 3.45M | 3.00M | 3.21M | 2.94M | 3.38M | 3.69M | 3.25M | 3.30M |
Interest Income | 0.00 | 0.00 | 1.68K | 2.10K | 571.05 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Interest Expense | 1.11M | 1.47M | 1.68M | 2.10M | 571.05K | 679.69K | 1.17M | 2.89M | 1.19M | 6.06K | -975.99K | 975.99K | 423.37K | 55.15K | 52.37K | 51.79K | 70.86K | 68.78K | 85.84K | 78.12K |
Depreciation & Amortization | 186.72K | 73.61K | 741.60K | 171.06K | 63.98K | 24.71K | 3.40M | 1.00 | 0.00 | 0.00 | 0.00 | 7.57K | 10.52K | 7.82K | -3.10K | 17.91K | 15.23K | 14.62K | 15.23K | 16.39K |
EBITDA | -549.06K | -2.23M | -3.08M | -1.21M | -3.96M | -243.61K | 4.03M | -3.87M | -1.44M | -1.11M | -6.51M | 3.62M | -17.49M | -4.14M | -1.86M | -836.43K | -2.05M | -2.29M | -1.14M | -2.00M |
EBITDA Ratio | -274,528.00% | -5,330.14% | -110.77% | -28.19% | -401.68% | -3,495.76% | -3,680.43% | -8,084.79% | -657.31% | -281.19% | -132.57% | -131.85% | -222.14% | -154.04% | -135.15% | -66.48% | -158.52% | -164.31% | -29.14% | -111.43% |
Operating Income | -925.82K | -2.19M | -2.42M | -1.21M | -1.88M | -6.32M | -1.63M | -2.67M | -1.45M | -1.12M | -1.40M | -1.40M | -2.38M | -1.92M | -1.93M | -1.19M | -2.05M | -2.30M | -1.16M | -2.02M |
Operating Income Ratio | -462,911.00% | -5,515.16% | -410.14% | -32.85% | -415.86% | -3,482.91% | -3,889.59% | -8,084.79% | -657.31% | -281.19% | -132.57% | -132.57% | -223.13% | -163.16% | -141.24% | -67.50% | -154.99% | -165.95% | -55.19% | -157.44% |
Total Other Income/Expenses | -924.14K | -1.58M | -3.09M | -2.85M | -2.72M | 5.96M | 4.48M | -4.09M | -1.18M | 524.00 | -5.13M | 4.03M | -15.54M | -2.28M | 16.45K | 279.07K | -8.81K | 178.83K | -62.13K | 99.89K |
Income Before Tax | -1.85M | -3.78M | -5.51M | -4.06M | -4.60M | -8.13M | 2.85M | -6.76M | -2.63M | -1.12M | 800.00 | 2.64M | -17.93M | -4.20M | -1.91M | -906.13K | -2.06M | -2.12M | -1.22M | -1.92M |
Income Before Tax Ratio | -924,981.50% | -9,492.70% | -934.71% | -110.47% | -1,019.42% | -4,478.93% | 6,821.37% | -20,435.48% | -1,191.81% | -281.06% | 0.08% | 250.56% | -1,677.49% | -356.68% | -140.03% | -51.61% | -155.65% | -153.05% | -58.16% | -149.64% |
Income Tax Expense | 2.00 | 0.00 | 1.68M | -753.70 | 580.52K | 800.00 | 800.00 | 800.00 | 800.00 | 800.00 | 800.00 | 800.00 | 800.00 | 800.00 | 800.00 | 800.00 | 800.00 | 800.00 | 800.00 | 800.00 |
Net Income | -1.85M | -3.78M | -7.19M | -4.06M | -5.18M | -8.13M | 2.85M | -6.76M | -2.63M | -1.12M | 2.64M | 2.64M | -17.93M | -4.20M | -1.91M | -906.93K | -2.06M | -2.12M | -1.22M | -1.92M |
Net Income Ratio | -924,981.50% | -9,492.70% | -1,220.69% | -110.47% | -1,148.08% | -4,479.37% | 6,819.46% | -20,437.90% | -1,192.18% | -281.26% | 250.49% | 250.49% | -1,677.56% | -356.75% | -140.09% | -51.65% | -155.71% | -153.10% | -58.19% | -149.70% |
EPS | 0.00 | -0.01 | -0.01 | -0.01 | -0.04 | -0.25 | 0.21 | -0.64 | -0.29 | -0.15 | 0.02 | 0.20 | -0.91 | -0.22 | -0.13 | -0.07 | -0.19 | -0.22 | -0.14 | -0.25 |
EPS Diluted | 0.00 | -0.01 | -0.01 | -0.01 | -0.04 | -0.25 | 0.18 | -0.64 | -0.29 | -0.15 | 0.02 | 0.07 | -0.91 | -0.22 | -0.13 | -0.07 | -0.19 | -0.22 | -0.14 | -0.25 |
Weighted Avg Shares Out | 901.40M | 670.66M | 515.34M | 498.23M | 140.04M | 32.12M | 13.83M | 10.64M | 9.20M | 7.49M | 149.75M | 25.00M | 19.63M | 18.84M | 14.73M | 12.18M | 10.60M | 9.72M | 8.53M | 7.76M |
Weighted Avg Shares Out (Dil) | 901.40M | 670.66M | 515.34M | 498.23M | 140.04M | 32.12M | 15.67M | 10.64M | 9.20M | 7.49M | 149.75M | 37.50M | 19.63M | 18.84M | 14.73M | 12.18M | 10.60M | 9.72M | 8.53M | 7.76M |
Grapefruit USA Reports Cannabis Bumper Crop, Lower Demand due to Pandemic and Economic Uncertainty Contributed to Small Year-over-Year Revenue Decrease
Grapefruit USA, Inc. Issues Further Update Concerning Formation of Joint Venture with Canadian Partner to Distribute Hourglass Products; Possible Acquisition
Cannabis Meets Crypto at Grapefruit's New CBD Hourglass E-Commerce Store
Grapefruit Launches New E-Commerce Store, Providing Nationwide One-Stop Shop for Its THC-Free, Hemp-Derived, Hourglass-Powered CBD Topical Cream
Grapefruit USA, Inc. Reports 714% Year-Over-Year Revenue Growth Despite Global Pandemic
Grapefruit's New E-Commerce Store to Provide a One-Stop Shop for Its Hourglass Hemp-Derived CBD Topical Cream
Seasoned Media and Digital Marketing Executive Sharon Boddie Joins Grapefruit Board of Directors
Grapefruit Advances the Hourglass' THC/CBD-Infused Particle Structure for Increased Bioavailability
Grapefruit USA, Inc. Announces Hourglass™ Time Release THC+CBD Delivery Cream is Now Available on Crown Genetics Mobile Retail Distribution Platform
Grapefruit USA, Inc. Signs Digital Services Consulting Agreement
Source: https://incomestatements.info
Category: Stock Reports